Abstract: A process is provided for preparing novel substituted or unsubstituted 4(5)-.omega.-aminoalkyl)imidazoles of the formula ##STR1## wherein n is 1 to 6, R.sub.1 is hydrogen or a linear, branched or cyclic, saturated or unsaturated alkyl group having 1-6 C-atoms or a phenyl ring being unsubstituted, or mono- or di-substituted with groups such as lower alkyl, halogen, alkoxy, methylenedioxy or a combination thereof, and R.sub.2 is hydrogen or methyl. The process comprises brominating an .omega.-phthalimidoalkan-2-one with bromine in anhydrous methanol to a 1- or 3-bromo-.omega.-phthalimido-alkan-2-one, subjecting said derivative to ring closure with an amidine in N.N-dimethylformamide with potassium carbonate under mild conditions followed by hydrolytic separation of the phthalic residue. Pharmaceutical compounds, compositions and a method of treatment are also provided.

Abstract: The invention relates to novel quinazoline and isoquinoline derivatives of the general formula: ##STR1## and acid addition salts and copper complexes thereof, wherein X represents nitrogen or a CH group,Y represents oxygen or an NH group,R.sub.1 and R.sub.2 represent hydrogen, alkyl(1-6 C), alkoxy (1-6 C), halogen or trifluoromethyl,R.sub.3 represents a substituted or unsubstituted 2-pyridyl group andR.sub.4 represents hydrogen, an alkyl(1-6 C) group unsubstituted or substituted by halogen, alkoxy (1-6 C) or phenyl groups, a cyclic alkyl group or a substituted or unsubstituted aromatic group.